652. MGUS, Amyloidosis, and Other Non-Myeloma Plasma Cell Dyscrasias: Clinical and Epidemiological: Poster II
0 activities
A Novel Approach to Lower Risk Monoclonal Gammopathy of Undetermined Significance (MGUS) Follow-up Based on Isotype-Specific Annualised Progression Risk: A Retrospective Real World Evidence Single Centre UK Study
1 activities
A Novel Approach to Lower Risk Monoclonal Gammopathy of Undetermined Significance (MGUS) Follow-up Based on Isotype-Specific Annualised Progression Risk: A Retrospective Real World Evidence Single Centre UK Study
A Phase III, Randomized Study of Daratumumab, Cyclophosphamide, Bortezomib and Dexamethasone (DARA-VCD) Induction Followed By Autologous Stem Cell Transplant or Dara-VCD Consolidation and Daratumumab Maintenance in Patients with Newly Diagnosed AL Am...
1 activities
A Phase III, Randomized Study of Daratumumab, Cyclophosphamide, Bortezomib and Dexamethasone (DARA-VCD) Induction Followed By Autologous Stem Cell Transplant or Dara-VCD Consolidation and Daratumumab Maintenance in Patients
Clinical Characteristics and Therapeutic Response of Patients with Heavy Chain (AH) and Heavy and Light Chain (AHL) Amyloidosis
1 activities
Clinical Characteristics and Therapeutic Response of Patients with Heavy Chain (AH) and Heavy and Light Chain (AHL) Amyloidosis
Clinicopathological and Gene Expression Analysis of Hyaline Vascular Castleman Disease
1 activities
Clinicopathological and Gene Expression Analysis of Hyaline Vascular Castleman Disease
Diagnosis of AL Amyloidosis Versus Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma Using FTIR/ML Analysis of Serum
1 activities
Diagnosis of AL Amyloidosis Versus Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma Using FTIR/ML Analysis of Serum
Distinguishing between Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma with FTIR/ML of Serum
1 activities
Distinguishing between Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma with FTIR/ML of Serum
Early Versus Delayed Intervention in Smoldering Multiple Myeloma: A Meta-Analysis of Clinical Trials
1 activities
Early Versus Delayed Intervention in Smoldering Multiple Myeloma: A Meta-Analysis of Clinical Trials
Exploring the Cell-Free Transcriptome As Biomarker Source in IgM Gammopathies: New Insights from the Fondazione Italiana Linfomi “BIO-WM” Trial
1 activities
Exploring the Cell-Free Transcriptome As Biomarker Source in IgM Gammopathies: New Insights from the Fondazione Italiana Linfomi “BIO-WM” Trial
Gain or Amplification of 1q21 in Systemic Light Chain Amyloidosis Is Associated with Advanced Mayo Stage, Plasma Cell Disease and Worse Overall Survival
1 activities
Gain or Amplification of 1q21 in Systemic Light Chain Amyloidosis Is Associated with Advanced Mayo Stage, Plasma Cell Disease and Worse Overall Survival
Implementing Revised Reference Intervals for Free Light Chains Improves Risk Stratification of Monoclonal Gammopathy of Undetermined Significance
1 activities
Implementing Revised Reference Intervals for Free Light Chains Improves Risk Stratification of Monoclonal Gammopathy of Undetermined Significance
Minimal Residual Disease Testing in Relapsed Systemic AL Amyloidosis
1 activities
Minimal Residual Disease Testing in Relapsed Systemic AL Amyloidosis
Predictors of Liver Response in Light Chain (AL) Amyloidosis: A Study with 130 Patients
1 activities
Predictors of Liver Response in Light Chain (AL) Amyloidosis: A Study with 130 Patients
Proteomic Determinants of Renal Organ Response in AL Amyloidosis
1 activities
Proteomic Determinants of Renal Organ Response in AL Amyloidosis
Real-World Outcomes of Monoclonal Gammopathy of Renal Significance (MGRS) in the Era of Novel Therapies
1 activities
Real-World Outcomes of Monoclonal Gammopathy of Renal Significance (MGRS) in the Era of Novel Therapies
Single-Center Retrospective Analysis of Autologous Stem Cell Transplantation for Patients with Systemic Light Chain Amyloidosis
1 activities
Single-Center Retrospective Analysis of Autologous Stem Cell Transplantation for Patients with Systemic Light Chain Amyloidosis